Literature DB >> 18213629

Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer.

Alan A Aitchison1, Abhi Veerakumarasivam, Maria Vias, Rajeev Kumar, Freddie C Hamdy, David E Neal, Ian G Mills.   

Abstract

BACKGROUND: Transforming growth factor-beta (TGF-beta) is a potent growth inhibitor in a wide range of cell types. A transducer of TGF-beta signaling known as Mothers against decapentaplegic homologue 4 (Smad4) is a known tumor suppressor found on chromosome 18q21.1 and is typically inactivated by deletion or mutation in pancreatic and colorectal cancers. The purpose of the article is to investigate Smad4 expression, gene copy number and methylation status in advanced cases of prostate cancer.
METHODS: We have employed Methylation Specific PCR (MSP) to identify methylation sites within the Smad4 promoter and combined this with quantitative real-time PCR to look for correlates between methylation status and Smad4 expression and to examine androgen receptor (AR) expression. Bacterial artificial chromosome-comparative genomic hybridization (BAC-CGH) has been used to look for genomic amplifications and deletions which may also contribute to expression changes.
RESULTS: We fail to find evidence of genomic deletions or amplifications affecting the Smad4 locus on chromosome 18 but show a correlation between promoter methylation and the loss of Smad4 expression in the same material. We confirm that the AR locus on the X chromosome is amplified in 30% of the advanced clinical samples and that this correlates with increased transcript levels as previously reported by other groups.
CONCLUSION: This indicates that epigenetic changes affect the expression of the Smad4 protein in prostate cancer and points to methylation of the promoter as a novel marker of and contributor to the disease warranting further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18213629     DOI: 10.1002/pros.20730

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  29 in total

1.  Concordant repression and aberrant methylation of transforming growth factor-beta signaling pathway genes occurs early in gastric cardia adenocarcinoma.

Authors:  Wei Guo; Zhiming Dong; Yanli Guo; Gang Kuang; Zhibin Yang; Baoen Shan
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

2.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.

Authors:  Zhihu Ding; Chang-Jiun Wu; Gerald C Chu; Yonghong Xiao; Dennis Ho; Jingfang Zhang; Samuel R Perry; Emma S Labrot; Xiaoqiu Wu; Rosina Lis; Yujin Hoshida; David Hiller; Baoli Hu; Shan Jiang; Hongwu Zheng; Alexander H Stegh; Kenneth L Scott; Sabina Signoretti; Nabeel Bardeesy; Y Alan Wang; David E Hill; Todd R Golub; Meir J Stampfer; Wing H Wong; Massimo Loda; Lorelei Mucci; Lynda Chin; Ronald A DePinho
Journal:  Nature       Date:  2011-02-02       Impact factor: 49.962

Review 3.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

4.  Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases.

Authors:  Zhihu Ding; Chang-Jiun Wu; Mariela Jaskelioff; Elena Ivanova; Maria Kost-Alimova; Alexei Protopopov; Gerald C Chu; Guocan Wang; Xin Lu; Emma S Labrot; Jian Hu; Wei Wang; Yonghong Xiao; Hailei Zhang; Jianhua Zhang; Jingfang Zhang; Boyi Gan; Samuel R Perry; Shan Jiang; Liren Li; James W Horner; Y Alan Wang; Lynda Chin; Ronald A DePinho
Journal:  Cell       Date:  2012-02-16       Impact factor: 41.582

5.  Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan.

Authors:  Chen Khuan Wong; Arthur W Lambert; Sait Ozturk; Panagiotis Papageorgis; Delia Lopez; Ning Shen; Zaina Sen; Hamid M Abdolmaleky; Balázs Győrffy; Hui Feng; Sam Thiagalingam
Journal:  Mol Cancer Res       Date:  2020-01-13       Impact factor: 5.852

Review 6.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

7.  Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells.

Authors:  Xueying Zhang; Junxia Cao; Yujun Pei; Jiyan Zhang; Qingyang Wang
Journal:  Oncol Lett       Date:  2016-04-07       Impact factor: 2.967

Review 8.  DNA methylation changes in prostate cancer: current developments and future clinical implementation.

Authors:  Mohammad Obaidul Hoque
Journal:  Expert Rev Mol Diagn       Date:  2009-04       Impact factor: 5.225

9.  Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness.

Authors:  Wei Jiang; Yi Zheng; Zhongxian Huang; Muwen Wang; Yinan Zhang; Zheng Wang; Xunbo Jin; Qinghua Xia
Journal:  Int Urol Nephrol       Date:  2013-11-22       Impact factor: 2.370

10.  Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer.

Authors:  Yongsheng Ren; Liyu Wu; Andra R Frost; William Grizzle; Xu Cao; Mei Wan
Journal:  Mol Cancer       Date:  2009-11-27       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.